PCSK9 and type 2 diabetes mellitus: Lipid-lowering therapies with PCSK9-specific antibodies or statins, which inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), are associated with an increased risk of new-onset T2D [26,27].